Ivonescimab (NCT06940518)

Name: Ivonescimab trial for Ivonescimab (NCT06940518)
Uploaded: 2026-10-31T21:47:21.886Z
Duration: 1 min 16 s
Description: Ivonescimab trial for Ivonescimab (NCT06940518). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06940518.

Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma: a one-minute explainerNCT069405181 min

Ivonescimab trial for Ivonescimab (NCT06940518). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with advanced or metastatic kidney cancer containing clear cells, after progression on checkpoint treatment.

The idea: ivonescimab targets PD-1 and VEGF, combining immune-brake blockade with inhibition of blood-vessel growth signals. Both groups receive infusions every three weeks. One group has no prior VEGF- or HIF-2-targeted treatment; the other requires prior VEGF treatment. Selected patients progressing during adjuvant checkpoint therapy can enter. Researchers assess responses, disease control, and safety.

This phase 2 study plans 40 patients. Pavlos Msaouel leads at MD Anderson in Houston, one US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.